IP Library › Granted Patent US 12,281,056
Granted Patent B2
US 12,281,056 · App. 18/499,120 · Granted Apr 22, 2025

Methods for making and using endoxifen

Inventors: Steven C. Quay (Seattle, WA); Yao-Lin Sun (Tainan, TW); LungHu Wang (Kaohsiung, TW); ChangJung Wu (Kaohsiung, TW); ChuanDer Huang (Tainan, TW)
Assignee: ATOSSA THERAPEUTICS, INC.
C07C217/18C07C213/10A61K9/0053A61K45/06C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,056
App. No.
18/499,120
Granted
Apr 22, 2025
Kind
B2
Abstract

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

Claims (76)

1. An oral formulation comprising an endoxifen formulated as an enteric tablet, an enteric caplet, or an enteric capsule, wherein:

(i) the endoxifen comprises a compound of Formula (III):

or a pharmaceutically acceptable salt thereof,

(ii) at least 90% by weight of the compound of Formula (III) is (Z)-endoxifen, and

(iii) the endoxifen comprises less than 2% impurities.

2. The oral formulation of claim 1 , wherein the endoxifen is endoxifen free base.

3. The oral formulation of claim 1 , wherein at least 95% by weight of the compound of Formula (III) is (Z)-endoxifen.

4. The oral formulation of claim 1 , wherein at least 97% by weight of the compound of Formula (III) is (Z)-endoxifen.

5. The oral formulation of claim 1 , wherein the endoxifen comprises less than 1% impurities.

6. The oral formulation of claim 1 , wherein the endoxifen comprises less than 0.5% impurities.

7. The oral formulation of claim 1 , wherein the endoxifen comprises one or more residual solvents selected from the group consisting of methanol, tetrahydrofuran, isopropanol, ethyl acetate, n-heptane, ethanol, and combinations thereof.

8. The oral formulation of claim 1 , wherein the endoxifen comprises no more than 3000 ppm methanol.

9. The oral formulation of claim 1 , wherein the endoxifen comprises no more than 720 ppm tetrahydrofuran.

10. The oral formulation of claim 1 , wherein the endoxifen comprises no more than 5000 ppm isopropanol.

11. The oral formulation of claim 1 , wherein the endoxifen comprises no more than 5000 ppm ethyl acetate.

12. The oral formulation of claim 1 , wherein the endoxifen comprises no more than 5000 ppm n-heptane.

13. The oral formulation of claim 1 , wherein the endoxifen comprises no more than 5000 ppm ethanol.

14. The oral formulation of claim 1 , wherein a water content of the endoxifen is not more than 1.0% as tested by Method Ic of USP 921.

15. The oral formulation of claim 1 , wherein the endoxifen comprises no more than 20 ppm of heavy metals.

16. The oral formulation of claim 1 , wherein the endoxifen is stable for at least 9 months at 25° C. and 60% relative humidity.

17. The oral formulation of claim 1 , wherein the endoxifen is stable for at least 3 months at 40° C. and 75% relative humidity.

18. The oral formulation of claim 1 , wherein the oral formulation is a delayed-release formulation.

19. The oral formulation of claim 1 , formulated such that the oral formulation is resistant to dissolution in an acidic environment for at least 2 hours, as measured in a dissolution test performed according to a method of USP 711.

20. The oral formulation of claim 1 , formulated such that the oral formulation releases no more than 10% of the (Z)-endoxifen over 2 hours in gastric fluid, as measured in a dissolution test performed according to a method of USP 711.

21. The oral formulation of claim 1 , formulated such that the oral formulation releases at least 50% of the (Z)-endoxifen within 8 hours in intestinal fluid, as measured in a dissolution test performed according to a method of USP 711.

22. The oral formulation of claim 1 , wherein the oral formulation comprises from 1 mg to 20 mg of (Z)-endoxifen.

23. The oral formulation of claim 1 , wherein the oral formulation comprises from 1 mg to 4 mg of (Z)-endoxifen.

24. The oral formulation of claim 1 , wherein the oral formulation comprises 8 mg of (Z)-endoxifen.

25. The oral formulation of claim 1 , wherein the oral formulation comprises from 20 mg to 200 mg of (Z)-endoxifen.

26. The oral formulation of claim 1 , wherein the oral formulation comprises endoxifen in polymorphic Form I, wherein polymorphic Form I is characterized by an X-ray powder diffraction pattern comprising peaks at 16.8±0.3°, 17.1±0.3° and 21.8±0.3° two theta.

27. An oral formulation comprising an endoxifen formulated as an enteric tablet, an enteric caplet, or an enteric capsule, wherein:

(i) the endoxifen comprises a compound of Formula (III):

or a pharmaceutically acceptable salt thereof,

(ii) at least 90% by weight of the compound of Formula (III) is (Z)-endoxifen, and

(iii) the (Z)-endoxifen is stable for at least 9 months at 25° C. and 60% relative humidity.

28. The oral formulation of claim 27 , wherein the endoxifen is endoxifen free base.

29. The oral formulation of claim 27 , wherein the endoxifen comprises less than 2% impurities.

30. The oral formulation of claim 27 , wherein the endoxifen is stable for at least 3 months at 40° C. and 75% relative humidity.

31. The oral formulation of claim 27 , wherein the oral formulation comprises endoxifen in polymorphic Form I, wherein polymorphic Form I is characterized by an X-ray powder diffraction pattern comprising peaks at 16.8±0.3°, 17.1±0.3° and 21.8±0.3° two theta.

32. A method comprising administering to a subject an oral formulation comprising an endoxifen, wherein:

(i) the endoxifen comprises a compound of Formula (III):

or a pharmaceutically acceptable salt thereof,

(ii) at least 90% by weight of the compound of Formula (III) is (Z)-endoxifen, and

(iii) the endoxifen comprises less than 2% impurities;

wherein the oral formulation is in a form of an enteric tablet, an enteric caplet, or an enteric capsule.

33. The method of claim 32 , wherein the endoxifen is endoxifen free base.

34. The method of claim 32 , wherein at least 95% by weight of the compound of Formula (III) is (Z)-endoxifen.

35. The method of claim 32 , wherein at least 97% by weight of the compound of Formula (III) is (Z)-endoxifen.

36. The method of claim 32 , wherein the endoxifen comprises less than 1% impurities.

37. The method of claim 32 , wherein the endoxifen comprises less than 0.5% impurities.

38. The method of claim 32 , wherein the endoxifen comprises one or more residual solvents selected from the group consisting of methanol, tetrahydrofuran, isopropanol, ethyl acetate, n-heptane, ethanol, and combinations thereof.

39. The method of claim 32 , wherein the endoxifen comprises no more than 3000 ppm methanol, no more than 720 ppm tetrahydrofuran, no more than 5000 ppm isopropanol, no more than 5000 ppm ethyl acetate, no more than 5000 ppm n-heptane, no more than 5000 ppm ethanol, or a combination thereof.

40. The method of claim 32 , wherein the endoxifen is stable for at least 9 months at 25° C. and 60% relative humidity.

41. The method of claim 32 , wherein the endoxifen is stable for at least 3 months at 40° C. and 75% relative humidity.

42. The method of claim 32 , comprising administering 1 mg to 20 mg of (Z)-endoxifen.

43. The method of claim 32 , comprising administering 1 mg to 4 mg of (Z)-endoxifen.

44. The method of claim 32 , comprising administering 8 mg of (Z)-endoxifen.

45. The method of claim 32 , wherein the administering of the oral formulation maintains the subject's plasma endoxifen at a steady state level above 30 nM.

46. The method of claim 32 , wherein the administering of the oral formulation maintains the subject's plasma endoxifen at a steady state level from 30 nM to 300 nM.

47. The method of claim 32 , further comprising releasing no more than 10% of the (Z)-endoxifen in a stomach of the subject within 2 hours following the administrating of the oral formulation.

48. The method of claim 32 , further comprising releasing at least 50% of the (Z)-endoxifen in a small intestine of the subject within 8 hours following the administrating of the oral formulation.

49. The method of claim 32 , further comprising producing an area under curve (AUC 0-inf ) of (Z)-endoxifen in the subject of from 200 hr*ng/ml to 10,000 hr*ng/ml per 4 mg of (Z)-endoxifen administered.

50. The method of claim 32 , further comprising producing a maximum blood plasma concentration (C max ) of (Z)-endoxifen in the subject of from 14 ng/ml to 62 ng/ml per 4 mg of (Z)-endoxifen administered.

51. The method of claim 32 , further comprising treating a hormone-dependent breast disorder or a hormone-dependent reproductive tract disorder in the subject in need thereof.

52. The method of claim 51 , wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is a benign breast disorder, hyperplasia, atypia, atypical ductal hyperplasia, atypical lobular hyperplasia, increased breast density, gynecomastia, ductal carcinoma in situ, lobular carcinoma in situ, breast cancer, precocious puberty, McCune-Albright Syndrome, endometrial cancer, ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, or vulvar cancer.

53. The method of claim 51 , wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is tamoxifen-refractory or tamoxifen resistant.

54. A method comprising administering to a subject an oral formulation comprising an endoxifen, wherein:

(i) the endoxifen comprises a compound of Formula (III):

or a pharmaceutically acceptable salt thereof,

(ii) at least 90% by weight of the compound of Formula (III) is (Z)-endoxifen, and

(iii) the endoxifen is stable for at least 9 months at 25° C. and 60% relative humidity;

wherein the oral formulation is in a form of an enteric tablet, an enteric caplet, or an enteric capsule.

55. The method of claim 54 , wherein the endoxifen is endoxifen free base.

56. The method of claim 54 , wherein the endoxifen is stable for at least 3 months at 40° C. and 75% relative humidity.

57. The method of claim 54 , wherein the endoxifen comprises less than 2% impurities.

58. The method of claim 54 , wherein the oral formulation comprises endoxifen in polymorphic Form I, wherein polymorphic Form I is characterized by an X-ray powder diffraction pattern comprising peaks at 16.8±0.3°, 17.1±0.3° and 21.8±0.3° two theta.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2024
From: QUAY, STEVEN C.
To: ATOSSA THERAPEUTICS, INC.
Reel/Frame 067708/0317 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2024
From: SUN, YAO-LIN; WANG, LUNGHU; WU, CHANGJUNG; HUANG, CHUANDER
To: KRISAN BIOTECH CO., LTD.
Reel/Frame 067708/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2024
From: KRISAN BIOTECH CO., LTD.
To: ATOSSA THERAPEUTICS, INC.
Reel/Frame 067708/0751 →
Continuity (9)
Continuation 18128536 · Mar 30, 2023
Continuation 18090757 · Dec 29, 2022
Continuation 17580428 · Jan 20, 2022
Continuation 16641985
Provisional Application 62693885 · Jul 3, 2018
Provisional Application 62624787 · Jan 31, 2018
Provisional Application 62556884 · Sep 11, 2017
Provisional Application 62556799 · Sep 11, 2017
Related Publication 20240327333A1 · Oct 3, 2024
References Cited (221)
US 3848030A · Viterbo et al. · 1974 [cited by applicant]
US 4851433A · Kraus · 1989 [cited by applicant]
US 6774122B2 · Evans et al. · 2004 [cited by applicant]
US 7384418B2 · Hung et al. · 2008 [cited by applicant]
US 7485623B2 · Bua · 2009 [cited by applicant]
US 7507769B2 · Nestour · 2009 [cited by applicant]
US 7531578B2 · Forman et al. · 2009 [cited by applicant]
US 7704516B2 · Drouin et al. · 2010 [cited by applicant]
US 7705159B2 · Macdonald et al. · 2010 [cited by applicant]
US 7786172B2 · De Lignieres et al. · 2010 [cited by applicant]
US 7968532B2 · Le Nestour et al. · 2011 [cited by applicant]
US 8048927B2 · Le Nestour · 2011 [cited by applicant]
US 8058302B2 · Solanki et al. · 2011 [cited by applicant]
US 8063249B1 · Kushner et al. · 2011 [cited by applicant]
US 8119695B2 · Forman et al. · 2012 [cited by applicant]
US 8329680B2 · Evans et al. · 2012 [cited by applicant]
US 8436029B2 · Hickey et al. · 2013 [cited by applicant]
US 8454945B2 · McCook et al. · 2013 [cited by applicant]
US 8466139B2 · Evans et al. · 2013 [cited by applicant]
US 8822511B2 · Combs et al. · 2014 [cited by applicant]
US 8993605B2 · Combs et al. · 2015 [cited by applicant]
US 9073875B2 · Boyall et al. · 2015 [cited by applicant]
US 9090640B2 · Bierbach et al. · 2015 [cited by applicant]
US 9200045B2 · Liu et al. · 2015 [cited by applicant]
US 9220680B2 · Perumal et al. · 2015 [cited by applicant]
US 9308181B2 · Kisak et al. · 2016 [cited by applicant]
US 9333190B2 · Ahmad et al. · 2016 [cited by applicant]
US 11261151B2 · Quay et al. · 2022 [cited by applicant]
US 11572334B2 · Quay et al. · 2023 [cited by applicant]
US 11680036B1 · Quay et al. · 2023 [cited by applicant]
US 12071391B2 · Quay · 2024 [cited by examiner]
US 20020025543A1 · Serrero · 2002 [cited by applicant]
US 20030021787A1 · Hung et al. · 2003 [cited by applicant]
US 20030099694A1 · Cevc et al. · 2003 [cited by applicant]
US 20030147950A1 · Platteeuw et al. · 2003 [cited by applicant]
US 20040092894A1 · Hung et al. · 2004 [cited by applicant]
US 20060280795A1 · Penhasi et al. · 2006 [cited by applicant]
US 20070059288A1 · Dinsmore et al. · 2007 [cited by applicant]
US 20070161063A1 · Love et al. · 2007 [cited by applicant]
US 20070190019A1 · Guo et al. · 2007 [cited by applicant]
US 20080138391A1 · Carrara et al. · 2008 [cited by applicant]
US 20080319092A1 · Singh · 2008 [cited by applicant]
US 20090068190A1 · Bortz · 2009 [cited by applicant]
US 20090098069A1 · Vacca · 2009 [cited by applicant]
US 20090208944A1 · Goetz et al. · 2009 [cited by applicant]
US 20090281063A1 · Inagi et al. · 2009 [cited by applicant]
US 20090291102A1 · Fortin · 2009 [cited by applicant]
US 20090291134A1 · Ahmad et al. · 2009 [cited by applicant]
US 20100015195A1 · Jain et al. · 2010 [cited by applicant]
US 20100015200A1 · McClain et al. · 2010 [cited by applicant]
US 20100069781A1 · Johansen et al. · 2010 [cited by applicant]
US 20100098659A1 · Watson et al. · 2010 [cited by applicant]
US 20100112041A1 · Ahmad et al. · 2010 [cited by applicant]
US 20120010245A1 · Masini-Eteve · 2012 [cited by applicant]
US 20120149761A1 · Quay · 2012 [cited by applicant]
US 20120164075A1 · Ahmad et al. · 2012 [cited by applicant]
US 20120301541A1 · Haronsky et al. · 2012 [cited by applicant]
US 20130046171A1 · Johansen et al. · 2013 [cited by applicant]
US 20130177590A1 · Combs et al. · 2013 [cited by applicant]
US 20130197087A1 · Schlotzer et al. · 2013 [cited by applicant]
US 20140088059A1 · Perumal et al. · 2014 [cited by applicant]
US 20140193334A1 · Bierbach et al. · 2014 [cited by applicant]
US 20140199391A1 · Birbara · 2014 [cited by applicant]
US 20150080339A1 · Wang et al. · 2015 [cited by applicant]
US 20150132388A1 · Angi et al. · 2015 [cited by applicant]
US 20150141391A1 · Chinnaiyan et al. · 2015 [cited by applicant]
US 20150250802A1 · Labrie et al. · 2015 [cited by applicant]
US 20160045502A1 · Brown · 2016 [cited by applicant]
US 20160346230A1 · Ahmad et al. · 2016 [cited by applicant]
US 20160375234A1 · Quay · 2016 [cited by applicant]
US 20170145515A1 · Chen et al. · 2017 [cited by applicant]
US 20170304232A1 · Khan et al. · 2017 [cited by applicant]
US 20180049999A1 · Quay · 2018 [cited by applicant]
US 20180200206A1 · Quay · 2018 [cited by applicant]
US 20190269697A1 · Labrie · 2019 [cited by applicant]
US 20200207704A1 · Quay et al. · 2020 [cited by applicant]
US 20230365490A1 · Quay et al. · 2023 [cited by applicant]
CN 101891635A · 2010 [cited by applicant]
CN 102448467A · 2012 [cited by applicant]
CN 104203961A · 2014 [cited by applicant]
CN 104352504A · 2015 [cited by applicant]
CN 105579044A · 2016 [cited by applicant]
CN 104230723B · 2016 [cited by applicant]
EP 1731142A1 · 2006 [cited by applicant]
EP 2101731A2 · 2009 [cited by applicant]
EP 2350111A1 · 2011 [cited by applicant]
EP 2508174A1 · 2012 [cited by applicant]
EP 1709062B9 · 2013 [cited by applicant]
EP 3202420A1 · 2017 [cited by applicant]
EP 3202420B1 · 2020 [cited by applicant]
WO WO0064416A3 · 2001 [cited by applicant]
WO WO0174366A1 · 2001 [cited by applicant]
WO WO2008066783A2 · 2008 [cited by applicant]
WO WO2008070463A2 · 2008 [cited by applicant]
WO WO2008070463A9 · 2008 [cited by applicant]
WO WO2009032699A1 · 2009 [cited by applicant]
WO WO2009069140A1 · 2009 [cited by applicant]
WO WO2009120999A2 · 2009 [cited by applicant]
WO WO2009120999A3 · 2009 [cited by applicant]
WO WO2010066810A1 · 2010 [cited by applicant]
WO WO2010135703A2 · 2010 [cited by applicant]
WO WO2011072244A1 · 2011 [cited by applicant]
WO WO2012050263A1 · 2012 [cited by applicant]
WO WO2012089677A1 · 2012 [cited by applicant]
WO WO2013050280A1 · 2013 [cited by applicant]
WO WO2013134230A1 · 2013 [cited by applicant]
WO WO2014134165A1 · 2014 [cited by applicant]
WO WO2014141292A2 · 2014 [cited by applicant]
WO WO2014060640A8 · 2015 [cited by applicant]
WO WO2015106094A1 · 2015 [cited by applicant]
WO WO2015138340A1 · 2015 [cited by applicant]
WO WO2015187727A2 · 2015 [cited by applicant]
WO WO2016168021A1 · 2016 [cited by applicant]
WO WO2016187122A1 · 2016 [cited by applicant]
WO WO2017011623A1 · 2017 [cited by applicant]
WO WO2017070651A1 · 2017 [cited by applicant]
WO WO2017080770A1 · 2017 [cited by applicant]
WO WO2019051368A1 · 2019 [cited by applicant]
WO WO2019051370A1 · 2019 [cited by applicant]
WO WO2019051416A1 · 2019 [cited by applicant]
Ackerman A.B., et al., “Contrary View: The Breast is not an Organ Per Se, but a Distinctive Region of Skin and Subcutaneous Tissue,” The American Journal of Dermatopathology, Apr. 2007, vol. 29 (2), pp. 211-218. [cited by applicant]
Ahmad A., et al., “Endoxifen, A New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability and Systemic Bioavailability in Healthy Human Subjects,” Clinical Pharmacology & Therapeutics, Dec. 2010, v… [cited by applicant]
Ahmad A., et al., “Endoxifen, A New Treatment Option for Mania: A Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen,” Clinical and Translational Science, vol. 9 (5), Jun. 27, 2016, p… [cited by applicant]
Ahmad A., et al., “Endoxifen for Breast Cancer: Multiple Dose, Dose Escalation Study Characterizing Pharmacokinetics and Safety in Metastatic Breast Cancer Patients,” Journal of Clinical Oncology, vol. 30 (15), May 20, … [cited by applicant]
Ahmad A., et al., “Orally Administered Endoxifen is a New Therapeutic Agent for Breast Cancer,” Breast Cancer Research Treatment, vol. 122 (2), Jul. 2010, pp. 579-584. [cited by applicant]
Ali et al., Endoxifen is a new potent inhibitor of Pkc: A potential therapeutic agent for bipolar disorder. Bioorganic & Medicinal Chemistry Letters 20(8): 2665-2667 (2010). [cited by applicant]
Anonymous, “History of Changes for Study: NCT02547961,” Sep. 10, 2015, XP055669980, retrieved from the URL: https://clinicaltrials.gov/ct2/history/NCT02547961?V_1=View#StudyPageTop, on Feb. 19, 2020, 4 pages. [cited by applicant]
Aydiner, et al., “Meta-Analysis of Trials Comparing Anastrozole and Tamoxifen for Adjuvant Treatment of Oostmenopausal Women with Early Breast Cancer,” Trials, vol. 9 (47), Jul. 29, 2008, pp. 1-9. [cited by applicant]
Bao, et al., “The Clinical Pharmacology of Anastrozole,” European Oncology and Hematology, vol. 7 (2), 2011, pp. 106-108. [cited by applicant]
Bath, et al., “An Improved Sysnthesis of Raloxifene Hydrochoride: A Selective Estrogen Receptor Modulator,” Heteroletters, vol. 4 (4), 2014, pp. 515-518. [cited by applicant]
Bernhard H., et al., “Adoptive Transfer of Autologous, HER2-Specific, Cytotoxic T Lymphocytes for the Treatment of HER2-Overexpressing Breast Cancer,” Cancer Immunology, Immunotherapy, 2008, vol. 57, pp. 271-280. [cited by applicant]
Bhatnagar P., et al., “Tumor Lysing Genetically Engineered T Cells Loaded with Multi-Modal Imaging Agents,” Scientific Reports, vol. 4, No. 4502, DOI: 10.1038/srep04502, published on Mar. 28, 2014, 21 pages. [cited by applicant]
Chang M., “Tamoxifen Resistance in Breast Cancer,” Biomolecules Therapeutics, May 2012, vol. 20 (3), pp. 256-267. [cited by applicant]
Clinical Trials Government, Identifier No. NCT01273168, “Endoxifen in Adults With Hormone Receptor Positive Solid Tumors,” Jan. 10, 2011, 10 pages. [cited by applicant]
Clinical Trials Government, Identifier No. NCT02311933, “Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer,”… [cited by applicant]
Davison, et al., “In Vitro Effects on MCF-7 Breast Cancer Cells of Signal Transduction Inhibitor/Tamoxifen/ Eicosapentaenoic Acid Combinations and their Simultaneous Delivery Across Skin,” Pharmaceutical Research, vol. … [cited by applicant]
Dickschen K., et al., “Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance,” Frontiers in Pharmaco… [cited by applicant]
Donneyong M.M., et al., “Risk of Mortality with Concomitant use of Tamoxifen and Selective Serotonin Reuptake Inhibitors: Multi-Database Cohort Study,” BMJ, Sep. 30, 2016, vol. 354 (i5014), 20 pages. [cited by applicant]
Dowsett et al., The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. British J Cancer 1999; 79(2), 311-315. [cited by applicant]
Elkins P., et al., “Characterization of the Isomeric Configuration and Impurities of (Z)-endoxifen by 2D NMR, High Resolution LC-MS, and Quantitative HPLC Analysis,” Journal of Pharmaceutical and Biomedical Analysis, Ja… [cited by applicant]
European Application No. 20834248.5 Extended Search Report dated Jun. 29, 2023. [cited by applicant]
Extended European Search Report for EP Application EP17857260.8, dated Mar. 24, 2020, 16 pages. [cited by applicant]
Extended European Search Report for European Application No. EP18853361.6, dated May 28, 2021, 5 pages. [cited by applicant]
Fasching P.A., et al., “Ki67, Chemotherapy Response and Prognosis in Breast Cancer Patients receiving Neoadjuvant Treatment,” BMC Cancer, vol. 11, Article 486, 2011, 13 pages. [cited by applicant]
Fauq A.H., et al., “A Convenient Synthesis of (Z)-4-Hydroxy-N-Desmethyltamoxifen (Endoxifen),” Bioorganic and Medicinal Chemistry Letters, vol. 20 (10), 2010, pp. 3036-3038. [cited by applicant]
Forbes, et al., “Anastrozole Versus Tamoxifen for the Prevention of Locoregional and Contralateral Breast Cancer in Postmenopausal Women with Locally Excised Ductal Carcinoma in Situ (IBIS-II DCIS): A Double-Blind,” Ran… [cited by applicant]
Forefront., “Endoxifen Shows Promise As Breast Cancer Treatment”, Mayo Clinic Cancer Center's Online Magazine, vol. 3, Issue 1, 2014, 3 pages. [cited by applicant]
Galeana P. C., et al., “Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy,” The Oncologist, vol. 23 (6), Jun. 2018, pp. 670-678. [cited by applicant]
Gauthier S., et al., “New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction,” The Journal of Organic Chemistry, vol. 61(11), May 31, 1996, pp. 3890-3893. [cited by applicant]
Gelmon, et al., “Targeting Triple-Negative Breast Cancer: Optimizing Therapeutic Outcomes,” Annals of Oncology, vol. 23 (9), Sep. 2012, pp. 2223-2234. [cited by applicant]
Goetz M.P., et al., “A First-in-Human Phase I Study of the Tamoxifen (TAM) Metabolite, Z-Endoxifen Hydrochloride (Z-Endx) in Women with Aromatase Inhibitor (AI) Refractory Metastatic Breast Cancer (MBC) (NCT01327781),” … [cited by applicant]
Goetz M.P., et al., “Abstract PD2-03: Final Results of a First-in-Human Phase I Study of the Tamoxifen (TAM) Metabolite, Z-Endoxifen Hydrochloride (Z-Endx) in Women with Aromatase Inhibitor (AI) Refractory Metastatic Br… [cited by applicant]
Goetz M.P., et al., “Final Results of a First in Human Phase I Study of the Tamoxifen (TAM) Metabolite, Endoxifen Hydrochloride in Women with Aromatase Inhibitor (AI) Refractory Metastatic Breast Cancer (MBC) (NCT013277… [cited by applicant]
Goetz M.P., et al., “First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer,” DOI: https://ascopubs.org/doi/10.1200/JCO.2017.73.3246 , vol. 35, N… [cited by applicant]
“Hardness of Tablet Chart,” The 2nd Paragraph Under the Section Bending Test, Aug. 5, 2023, 26 pages. [cited by applicant]
Hawse J.R., et al., “Endoxifen's Molecular Mechanisms of Action are Concentration Dependent and Different than that of other Anti-Estrogens,” PLoS one, vol. 8 (1), Jan. 2013, e54613, 18 pages. [cited by applicant]
Henderson S.L., et al., “Profound Reduction in Tamoxifen Active Metabolite Endoxifen in a Breast Cancer Patient Treated with Rifampin Prior to Initiation of an Anti-TNF a Biologic for Ulcerative Colitis: a Case Report,”… [cited by applicant]
Hershman, et al., “Early Discontinuation and Non-adherence to Adjuvant Hormonal Therapy in a Cohort of 8, 769 early Stage Breast Cancer Patients,” Journal of Clinical Oncology, vol. 26(27), Sep. 20, 2010. [cited by applicant]
Ikeda H., et al., “Combination Treatment with Fulvestrant and various Cytotoxic Agents (Doxorubicin, Paclitaxel, Docetaxel, Vinorelbine, and 5-Fluorouracil) has a Synergistic Effect in Estrogen Receptor-Positive Breast … [cited by applicant]
Ingle, et al., “Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer,” Cancer Research, vol. 70 (8), Apr. 15, 2010, pp. 3278-3286. [cited by applicant]
International Preliminary Report on Patentability for the application No. PCT/US2020/040757, mailed Jan. 13, 2022, 9 pages. [cited by applicant]
International Report on Patentability for International Application No. PCT/US2018/050193, mailed Mar. 26, 2020, 7 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/050193, mailed Jan. 4, 2019, 9 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/050272, dated Jan. 3, 2019, 12 pages. [cited by applicant]
Jansen, et al., “High miR-26a and Low CDC2 Levels Associate with Decreased EZH2 Expression and with Favorable Putcome on Tamoxifen in Metastatic Breast Cancer,” Breast Cancer ResearchTreatment, vol. 133, 2012, pp. 937-9… [cited by applicant]
Jina Pharmaceuticals Inc, “Improved Pharmaceutical Composition of Endoxifen & Preparation Thereof,” 2015, 46 pages. [cited by applicant]
Johnson M.D., et al., “Pharmacological Characterization of 4-Hydroxy-N-Desmethyl Tamoxifen, A Novel Active Metabolite of Tamoxifen,” Breast Cancer Research and Treatment, vol. 85, 2004, pp. 151-159. [cited by applicant]
Johnson R.E., et al., “Gynecomastia—Evaluation and Current Treatment Options,” Therapeutics and Clinical Risk Management, vol. 7, 2011, pp. 145-148. [cited by applicant]
Jordan, C. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. Nov. 2007; 72(13): 829-842. [cited by applicant]
Journal of Pharmaceutical Science and Technology, Japan, 2006, vol. 66, No. 6, pp. 435-439. (No English Translation available. Document showing a well-known technique). [cited by applicant]
Kamdem, et al., “In Vitro and in Vivo Oxidative Metabolism and Glucuronidation of Anastrozole,” British Journal of Clinical Pharmacology, vol. 70 (6), 2010, pp. 854-869. [cited by applicant]
Karlsson H., et al., “CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma,” Gene Ther, Aug. 2015, vol. 26(8), https://pubmed.ncbi.nlm.nih.gov/26230974/ , pp. 498-505. [cited by applicant]
Kaur, et al., “Design, Synthesis and Evaluation of Ospemifene Analogs as Anti-Breast Cancer Agents,” European Journal of Medicinal Chemistry, vol. 86, Oct. 30, 2014, pp. 211-218. [cited by applicant]
Kebamo, et al., The Role of biotransformation in drug discovery and development. J Drug Metab. Toxicol. 2015; 6(5): 1-13. [cited by applicant]
Ku M.S., et al., “Performance Qualification of a New Hypromellose Capsule: Part I. Comparative Evaluation of Physical, Mechanical and Processability Quality Attributes of Vcaps Plus®, Quali-V® and Gelatin Capsules,” Int… [cited by applicant]
Lancet, “Aromatase Inhibitors Versus Tamoxifen in Early Breast Cancer: Patient-Level Meta-Analysis of the Randomised Trials,” vol. 386, 2015, pp. 1341-1352. [cited by applicant]
Lari, et al., “Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review,” Journal of Cancer, vol. 2, 2011, pp. 232-261. [cited by applicant]
Lazzeroni M., et al., “Oral Low Dose and Topical Tamoxifen for Breast Cancer Prevention: Modern Approaches for an Old Drug,” Breast Cancer Research, vol. 14(214), 2012, 11 pages, [Retrieved on Apr. 9, 2019] Retrieved fr… [cited by applicant]
Lee O., et al., “In Vitro Human Skin Permeation of Endoxifen: Potential for Local Transdermal Therapy for Primary Prevention and Carcinoma in Situ of the Breast,” Breast Cancer: Targets and Therapy, vol. 3, 2011, pp. 61… [cited by applicant]
Lee O., et al., “Local Transdermal Therapy to the Breast for Breast Cancer Prevention and DCIS Therapy: Preclinical and Clinical Evaluation,” Cancer Chemother Pharmacol, vol. 76(6), Dec. 2015, pp. 1235-1246. [cited by applicant]
Lehmann, “Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies,” Journal of Clinical Invest, vol. 121 (7), 2011, pp. 2750-2767. [cited by applicant]
Lemaine, et al., “Gynecomastia in Adolescent Males,” Seminars Plastic Surgery, vol. 27 (1), Feb. 2013, pp. 56-61. [cited by applicant]
Li L., et al., “Prognostic Values of Ki-67 in Neoadjuvant Setting for Breast Cancer: A Systematic Review and Meta-Analysis,” Future Oncology, vol. 13(11), May 2017, pp. 1021-1034. [cited by applicant]
Liby, et al., “The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or a colbifene, Synergizes in the Prevent and Treatment of Mammary Tumors in an Estrogen Receptor-… [cited by applicant]
Lim Y.C., et al., “Endoxifen (4-Hydroxy-N-Desmethyl-Tamoxifen) has Anti-Estrogenic Effects in Breast Cancer Cells with Potency Similar to 4-Hydroxy-Tamoxifen,” Cancer Chemother Pharmacol, 2005, vol. 55, pp. 471-478. [cited by applicant]
Love, et al., “A Feasibility Study of the Intraductal Administration of Chemotherapy,” Cancer Prevention Research, vol. 6, No. 1, Nov. 20, 2012, pp. 51-58. [cited by applicant]
Mah, et al., “A Miniaturized Flow-through Cell to Evaluate Skin Permeation of Endoxifen,” International Journal of pharmaceutics, vol. 441, 2013, pp. 433-440. [cited by applicant]
Mahoney M.E., et al., “Intraductal Therapy of Ductal Carcinoma In Situ: A Presurgery Study,” Clinical Breast Cancer, Aug. 2013, 13(4), pp. 280-286. [cited by applicant]
Manni et al: “Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention”, Biomed Research International, vol. 2015, Jan. 1, 2015 (Jan. 1, 2015), pp. 1-10, XP055561178, ISSN: 2314-6133, DOI: 10.11… [cited by applicant]
Mansel R., et al., “A Phase II Trial of Afimoxifene (4-hydroxy Tamoxifen gel) for Cyclical Mastalgia in Premenopausal Women,” Breast Cancer Research Treatment, Dec. 2007, vol. 106 (3), pp. 389-397. [cited by applicant]
Maximov P. Y., et al., “Structure-Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen,” Journal of Medicinal Chemistry, Apr. 22, 2010, vol. 53 (8), pp. 3273-3283. [cited by applicant]
Melnikow J., et al., “Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for Tamoxifen for Breast Cancer Risk Reduction,” Cancer, vol. 103 (10), May 15, 2005, pp. 1996-2005. [cited by applicant]
Memorial Sloan Kettering: “T-Cell Therapy for Advanced Breast Cancer,” 2016, pp. 1-8. [cited by applicant]
Miller, et al., “Stereospecific Synthesis of (Z)-Tamoxifen via Carbometallation of Alkynylsilanes,” The Journal of Organic Chemistry, vol. 50 (12), 1985, pp. 2121-2123. [cited by applicant]
Ogawa K., et al., “Synthesis and Antiestrogenic Activity of the Compounds Related to the Metabolites of (Z)-4-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-(4-isopropylphenyl)-1-butenyl]phenyl monophosphate (TAT-59), ” Chemi… [cited by applicant]
Oken M.M., et al., “Toxicity and Response Criteria of the Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology, Dec. 1982, vol. 5(6), pp. 649-655. [cited by applicant]
Partridge, et al., “Adherence to Initial Adjuvant Anastrozole Therapy among Women with Early Stage Breast Cancer,” Journal Clinical Oncology, Feb. 1, 2008, vol. 26 (4). [cited by applicant]
Partridge et al., Nonadherence to Adjuvant Tamoxifen Therapy in Women with Primary Breast Cancer. J. Clinical Oncology, vol. 21, Feb. 15, 2003. [cited by applicant]
Robertson, et al., “Fulvestrant: Pharmacokinetics and Pharmacology, ” British Journal of Cancer, 2004, vol. 90, pp. S7-S10. [cited by applicant]
Robertson, et al., “Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer,” Clinical Pharmacokinetics, 2004, vol. 43 (8), pp. 529-538. [cited by applicant]
Rouanet P., et al., “Neoadjuvant Percutaneous 4-Hydroxytamoxifen Decreases Breast Tumoral Cell Proliferation: A Prospective Controlled Randomized Study Comparing Three Doses of 4-hydroxytamoxifen Gel to Oral Tamoxifen,”… [cited by applicant]
Sano, et al., “Short-step Synthesis of Droloxifene via the Three-Component Coupling Reaction among Aromatic Aldehyde, Cinnamyltrimethylsilane, and 13-Chlorophenetole,” Tetrahedron Letters, Mar. 6, 2006, vol. 47 (10), pp… [cited by applicant]
Saravanan M. et al., “The Effect of Tablet Formulation and Hardness on in Vitro Release of Cephalexin from Eudragit L100 Based Extended Release Tablets,” Biol. Pharm. Bull., Apr. 2002, vol. 25, No. 4, pp. 541-545. [cited by applicant]
Search Report and Written Opinion for Singapore Patent Application No. SG11202002105W mailed Apr. 21, 2021, 8 pages. [cited by applicant]
Soltamox Oral Solution, Rx Only, Savient Pharmaceuticals, Inc, Aug. 25, 2005, 37 pages. [cited by applicant]
Stearns, et al., “Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer,” Science Translational Medicine, Oct. 26, 2011, vol. 3 (106), 19 pages, 106ra108. [cited by applicant]
Sun M., et al., “Construction and Evaluation of a Novel Humanized HER2-Specific Chimeric Receptor,” Breast Cancer Research, Jun. 11, 2014, vol. 16, No. R61, 10 pages. [cited by applicant]
Taiwanese Patent Application No. 107131790 Search Report dated Jun. 30, 2022. English Translation included. [cited by applicant]
Umareddy, et al., “Improved Process for Centchroman, A Selective Estrogen Receptor Modulator (SERM),” Journal of Chemical and Pharmaceutical Research, 2015, vol. 7 (7), pp. 736-741. [cited by applicant]
Umareddy, et al., “Total Synthesis of Lasofoxifene and Nafoxidine,” An International Journal for Rapid Communication of Synthetic Organic Chemistry, 2016, vol. 46 (4), pp. 309-313. [cited by applicant]
Vergote, et al., “Fulvestrant is an Effective and Well-Tolerated Endocrine Therapy for Postmenopausal Women with Advanced Breast Cancer,” Results from Clinical Trials, British Journal of Cancer, 90 (Suppl), 2004, pp. S1… [cited by applicant]
Welsh, J., “Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens”, Biochemistry and Cell Biology, vol. 72, No. 11-12, 1994, pp. 537-545, XP009511548, ISSN: 0829-8211. [cited by applicant]
Wu, et al., “Single Cell MicroRNA Analysis using Microftuidic Ftow Cytometry,” PLoS One, 2013, vol. 8 (1), e55044. [cited by applicant]
Wu X., et al., “The Tamoxifen Metabolite, Endoxifen, is a Potent Antiestrogen that Targets Estrogen Receptor Alpha for Degradation in Breast Cancer Cells,” Cancer Research, Mar. 1, 2009, vol. 69(5), , pp. 1722-1727. [cited by applicant]
Yan Yaodong., “Design and Development of Sustained-Release and Controlled-Release Formulations,” Chinese Medicine Science and Technology Publishing House, Jun. 30, 2006 (Jun. 30, 2006), pp. 421-428. [cited by applicant]
Yang Y., et al., “Dendron-Based Micelles for Topical Delivery of Endoxifen: A Potential Chemo- Preventive Medicine for Breast Cancer,” Advanced Functional Materials, 2014, vol. 24, pp. 2442-2449. [cited by applicant]
Yao, et al., “Synthesis and Reactivity of Potential Toxic Metabolites of Tamoxifen Analogues: Droloxifene and Toremifene a-Quinones,” Chemical Research in Toxicology, 2001, vol. 14 (12), pp. 1643-1653. [cited by applicant]
Yoneya, et al., “Thiochroman Derivative CH4986399, A New Nonsteroidal Estrogen Receptor Down-regulator, Is effective in Breast Cancer Models,” Anticancer Research, 2010, vol. 30, pp. 873-878. [cited by applicant]
Zhang B., et al., “The Safety Parameters of the Study on Intraductal Cytotoxic Agent Delivery to the Breast Before Mastectomy,” http://dx.doi.Org/10.3978/j.issn.1000-9604.2014.10.06 , Sep. 9, 2014, Chinese Journal of Ca… [cited by applicant]
Zhao Y., et al., “A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity,” The Journal of Immunology, https://www.resear… [cited by applicant]
Zheng et al., Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos. 35(10): 1942-1948 (2007). [cited by applicant]
Cited By (1)
US 12,479,790